Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660381 · ClinicalTrials.gov registry record · Phase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
A Phase 1 study of Cannabis Use Disorder, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06660381: Recruiting Phase 1 study of Cannabis Use Disorder, sponsored by Johns Hopkins University.
NCT06660381 is a Phase 1 study of Cannabis Use Disorder that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 12 participants, below the 109-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06660381, a Phase 1 study of Cannabis Use Disorder, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study will evaluate the therapeutic potential of psilocybin in people with Cannabis Use Disorder (CUD). This study will examine the impact of psilocybin treatment on cannabis use and related variables in 12 people with CUD. This is an open-label proof-of-concept trial in which participants will complete a 12-week course of study treatment including two psilocybin sessions with psychological support, and follow-up assessments 3 and 6 months after the first psilocybin session.
Primary Outcome
This information will be collected using a modified Timeline Follow-Back (TLFB) interview. The TLFB (past 30 days), uses a calendar with specific anchor dates to identify the quantity and frequency of use.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Maryland
- Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-11-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06660381 shows while recruiting
NCT06660381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 109-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06660381 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06660381 about?
NCT06660381 is a clinical study titled "Psilocybin-assisted Treatment for Cannabis Use Disorder". This pilot study will evaluate the therapeutic potential of psilocybin in people with Cannabis Use Disorder (CUD). This study will examine the impact of psilocybin treatment on cannabis use and related variables in 12 people with CUD. This is an open-label proof-of-concept trial in which participant...
What is the current status of trial NCT06660381?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-11-08. Estimated completion is 2026-12.
What conditions does trial NCT06660381 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT06660381?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06660381?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660381 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06660381's enrollment target sits among peer trials
12 32nd of 34 higher than 3 of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SCORE Emerging Adult Cannabis Use & Stress
RECRUITING · Phase 1
-
Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
RECRUITING · Phase 1
-
Mitigating PTSD-CUD After Sexual Assault
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
-
Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders
COMPLETED · Phase 1
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI